Xingchen Dong

Xingchen Dong

Auto-generated profile, based on publicly available information

Xingchen Dong

School of Chinese Materia Medica Nanjing University of Chinese Medicine Nanjing Jiangsu China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in FEBS Open Bio
Verified
Journal Article
Open access
XDXingchen Dong
Xingchen Dong
HLHuanhuan Li
Huanhuan Li
MPMin Pei
Min Pei
JTJie Tan
Jie Tan
GCGanjun Chen
Ganjun Chen
CWChunhe Wang
Chunhe Wang
Current treatment options for diabetic neuralgia are limited and unsatisfactory. Tanezumab, a monoclonal antibody that blocks nerve growth factor (NGF) signaling, has been shown to be effective in relieving the clinical symptoms of osteoarthritis pain, chronic low back pain, cancer pain induced by bone metastasis, and diabetic neuralgia. However, the clinical development of tanezumab has been terminated due to the risk of induction of rapidly progressive osteoarthritis (RPOA), and no other NGF antibodies have been examined for their ability to treat diabetic neuralgia in either animal models or clinical trials. In this study, a humanized high‐affinity NGF monoclonal antibody (mAb), huAb45 that could neutralize the interaction between NGF and its high‐affinity receptor TrkA. In a mouse diabetic neuralgia model, it effectively relieved neuropathic pain. This study may serve as the necessary foundation for future studies of huAb45 to potentially treat diabetic neuralgia.